1. Introduction {#sec1}
===============

The optic disc melanocytoma 'magnocellular nevus of optic disc\' is a rare benign melanocytic tumor that is usually innocent but sometimes it is difficult to be differentiated from juxta-papillary choroidal melanoma \[[@B1], [@B2]\]. It usually does not affect vision. However, visual impairment may occur in some cases secondary to vascular occlusion or rarely malignant transformation \[[@B1], [@B2]\]. Association between optic disc melanocytoma and choroidal neovascularization should be considered as one of the possible causes of diminution of vision in such patients. Different treatment options have been reported to be effective in treatment of such condition. This is a report of a case of optic disc melanocytoma presented with diminution of vision secondary to choroidal neovascularization (CNV), and intravitreal aflibercept was effective in the management of the associated CNV.

2. Case Report {#sec2}
==============

A 51-year-old male presented with a recent diminution of vision in his left eye of 2-month duration. The examination of the right eye was unremarkable. The ocular examination of the left eye disclosed a normal anterior segment, free ocular motility. The visual acuity of the left eye was 20/200. The fundus examination revealed a darkly pigmented mass with feathery margins on the superonasal aspect of the optic disc associated with a yellow peripapillary mass, intraretinal hemorrhages, and retinal edema adjacent to the temporal side of optic disc. Malignant transformation of melanocytoma was excluded based on absence of hemorrhage on the surface of the lesion or any signs of necrosis. Fluorescein angiography of left eye showed hypofluoresence of melanocytoma associated with early hyperfluorescence and late leakage in the temporal juxtapapillary area with deep retinal hemorrhage ([Figure 1](#fig1){ref-type="fig"}). Optical coherence tomography (OCT) showed diffuse macular thickening measuring about 800 microns with spongy edema, focal elevation of the retinal pigment epithelium temporal to the disc, and a shallow subfoveal neurosensory detachment, with absence of 'double layer sign\' ([Figure 2(a)](#fig2){ref-type="fig"}). Decision was taken to inject the patient with three intravitreal antivascular Endothelial Growth Factor (anti-VEGF) injections aflibercept (Eylea) one month apart between each of these injections. The visual acuity was improved to 20/40 using Snellen\'s chart. OCT was done one month after last injection showed complete resolution of macular edema ([Figure 2(b)](#fig2){ref-type="fig"}). At the 13-month follow-up period, the visual acuity is still 20/40 and dimensions of melanocytoma remained unchanged.

3. Discussion {#sec3}
=============

Optic disc melanocytoma is a benign pigmented tumor arising from melanocytes that rarely affects vision. The most common site of melanocytoma is the optic disc; however it may rarely arise in the orbit. \[[@B3]\] In a minority of patients, complications may develop such as vascular occlusion, choroidal neovascularization, polypoidal choroidal vasculopathy (PCV), visual field defects, afferent pupillary defect, or rarely malignant transformation \[[@B1], [@B2]\]. Choroidal neovascularization (CNV) is a variant of wet age-related macular degeneration. The association between PCV and optic disc melanocytoma has been rarely reported, with only 2 case reports in literature \[[@B4], [@B5]\]. In our case, absence of the "double layer sign," a typical sign of PCV on OCT, makes the diagnosis of PCV unlikely in our patient. OCT-Angiography was performed, and it did not show branching vascular network of PCV. These findings make the diagnosis of CNV more likely. However, it would have been better to do indocyanine green angiography to confirm the diagnosis and exclude PCV. CNV has been previously reported to be associated with optic disc melanocytoma with good response to intravitreal bevacizumab and ranibizumab as a method of treatment \[[@B9]--[@B12], [@B6]\]. To our knowledge, this the first case report to demonstrate the efficacy of aflibercept in the management of choroidal neovascularization associated with optic disc melanocytoma.

There are several methods of management choroidal neovascular membrane associated with optic disc melanocytoma including photodynamic therapy, submacular surgery, and intravitreal anti-VEGF injection \[[@B9], [@B8], [@B13]\] ([Table 1](#tab1){ref-type="table"}).

Less than 1% of cases of optic disc melanocytoma have been associated with CNV \[[@B6]\]. Although the relation between both signs is unclear, we agree with Kamisasaku et al. who postulated that the tumor may produce local inflammatory mediators disrupting the function of Bruch\'s membrane stimulating the choroid to produce a neovascular complex \[[@B10]\].

Intravitreal aflibercept is effective in treatment of CNV associated with disc melanocytoma.
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![(a) Fluorescein angiography of the left eye showing early hyperfluorescence in the temporal juxtapapillary region. (b) Fundus photography of the left eye.](CRIOPM2019-2672798.001){#fig1}

![(a) Optical coherence tomography (OCT) showing diffuse macular thickening. (b) OCT showing complete resolution of the macular edema.](CRIOPM2019-2672798.002){#fig2}

###### 

Review of previous reports on melanocytoma associated choroidal neovascularization (CNV).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case                                       Chalam \[[@B9]\],\     Tran \[[@B8]\],\                    Kamisasaku \[[@B10]\],\                   Al-Halafi \[[@B7]\],\                    Batmanabane et al. \[[@B11]\]            Urrets-Zavalia \[[@B12]\]   Rodrigues \[[@B13]\]                     Current case
                                             2006                   2006                                2012                                      2013                                                                                                                                                   
  ------------------------------------------ ---------------------- ----------------------------------- ----------------------------------------- ---------------------------------------- ---------------------------------------- --------------------------- ---------------------------------------- -----------------------------------------
  Age                                        Middle age             45 years                            63 years                                  45 years                                 28 years                                 50 years                    49 years                                 51 years

                                                                                                                                                                                                                                                                                                         

  Gender                                     Male                   \-                                  Male                                      Male                                     Female                                   Male                        Female                                   Male

                                                                                                                                                                                                                                                                                                         

  Affected eye                               Right                  left                                Left                                      Right                                    Left                                     Right                       Left                                     Left

                                                                                                                                                                                                                                                                                                         

  Primary presentation                       Diminution of vision   Diminution of vision                Diminution of vision                      Diminution of vision                     Diminution of vision                     Diminution of vision        Diminution of vision                     Diminution of vision

                                                                                                                                                                                                                                                                                                         

  Visual Acuity at 1^st^ presentation        20/200                 20/100                              0.9 LogMAR                                20/160                                   20/40                                    20/80                       Counting fingers 50 cm                   20/200

                                                                                                                                                                                                                                                                                                         

  Location of choroidal neovascularization   Juxtafoveal            Peripapilla y                       Adjacent to optic disc                    Juxtafoveal                              Peripapillary extending to the macula    Peripapillary               Macular                                  Peripapillary

                                                                                                                                                                                                                                                                                                         

  Treatment                                  Photodynamic therapy   Vitrectomy and submacular surgery   Intravitreal Bevacizumab (3 injections)   Intravitreal Bevacizumab (1 injection)   Intravitreal Ranibizumab (1 injection)   Intravitreal Bevacizumab    Intravitreal anti-VEGF was recommended   Intravitreal Aflibercept (3 injections)

                                                                                                                                                                                                                                                                                                         

  Follow-up                                  6 months               14 months                           12 months                                 12 months                                6 months                                 36 months                   Lost to follow-                          13 months
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[^1]: Academic Editor: Takaaki Hayashi
